MARFLOXIN 80 MG TABLETS FOR DOGS

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marfloxin 80 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablets.
Light brownish yellow, capsule shaped, biconvex, marble tablets with
possible dark and white spots and scored on the
both sides.
The tablets can be divided into halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by strains of microorganisms
susceptible to marbofloxacin in dogs:
skin and soft tissue infections (skinfold pyoderma, impetigo,
folliculitis, furunculosis, cellulitis);
urinary tract infections (UTI) associated or not with prostatitis or
epididymitis;
respiratory tract infections.
4.3 CONTRAINDICATIONS
Do not use in dogs aged less than 12 months, or less than 18 months
for exceptionally large breeds of dogs, such as
Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer
growth period.
Do not use in cats. For the treatment of this species, a 5 mg tablet
is available.
Do not use in animals with known hypersensitivity to marbofloxacin or
other (fluoro)quinolones or to any of the
excipients of the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
A low urinary pH could have an inhibitory effect on the activity of
marbofloxacin. Pyoderma occurs mostly secondary
to an underlying disease, thus, it is advisable to determine the
underlying cause and to treat the animal accordingly.
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
80 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
__
                                
                                Read the complete document